Morgan Stanley Starts Exscientia PLC (EXAI) at Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
UPDATE: BofA Securities Starts Exscientia PLC (EXAI) at Buy on AI Enabled Drug Platform
October 26, 2021 6:07 AM EDT(Updated - October 27, 2021 7:27 AM EDT)
BofA Securities analyst Michael Ryskin initiates coverage on Exscientia PLC (NASDAQ: EXAI) with a Buy rating and a price target of $27.00.
The analyst stated "Exscientia is a tech-enabled drug discovery platform company, leveraging artificial... More
